Please login to the form below

Not currently logged in
Email:
Password:

Astellas picks Dr Charlotte Kremer to lead new medical affairs organisation

She joins the pharma company from Pfizer to take up a new global role

Astellas Dr Charlotte KremerDr Charlotte Kremer has moved from Pfizer to Astellas to lead the Japanese pharma company's new global medical affairs organisation.

Based at Astellas' Illinois headquarters for its Americas operations, Dr Kremer will be tasked with providing “global leadership for medical excellence and a unified medical perspective”.

The company's Global Medical Affairs unit is one of its newest organisations and, although based in the US, may work with a variety of supporting positions from across the regions in which Astellas is active.

"We are thrilled to have Charlotte join Astellas. She brings years of experience and an outstanding reputation to this new, global leadership role," said Yoshihiko Hatanaka, president and CEO of Astellas Pharma Inc., the parent company of Astellas US LLC.

"Further globalising our key functions, such as medical affairs, is a top priority at Astellas because of the value it brings to the company in this competitive global business environment."

Dr Kremer has spent 20 years in the pharmaceutical industry, most recently serving at Pfizer as VP and therapeutic area head for ophthalmology, PVD, rare diseases and neuroscience.

Prior to joining Pfizer she worked at Organon in the Netherlands and the US, providing medical support, developing phase IIIb/IV clinical trials and initiated and developed a medical liaison programme.

23rd February 2012

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Valid Insight

Valid Insight is an award-winning pharmaceutical global market access consultancy....

Latest intelligence

New from the PhRMA: Diversity in clinical trials principles summarised
In November 2020, PhRMA announced the first-ever, industry-wide principles on clinical trial diversity. The principles were approved by the PhRMA Boards of Directors and will take effect in April 2021....
New from the FDA: Diversity in clinical trials guidance summarised
In November 2020, the FDA released guidance to enable greater diversity in clinical trials through changes to eligibility criteria, enrolment practices, and trial designs....
5 steps to effective clinical trial branding
When recruiting patients for your clinical trial, you want the materials and information around it to be seen as reputable and professional. To make it clear what the clinical trial...

Infographics